Amphastar Pharma (AMPH) Misses Q4 EPS by 3c

Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.88, $0.03 worse than the analyst estimate of $0.91. Revenue for the quarter came in at $178.1 million versus the consensus estimate of $173.35 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
• Pfizer reafffirms 2026 guidance after CFO transition announcement